Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation

Annals of Surgical Oncology

Volumn 16, Issue 2, 2009, Pages 431-439

  Chen, Jinyun ^a   Li, Donghui ^a   Killary, Ann M ^a,b   Sen, Subrata ^a,b   Amos, Christopher I ^a,b   Evans, Douglas B ^a   Abbruzzese, James L ^a   Frazier, Marsha L ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN MDM2; PROTEIN P16; PROTEIN P27; PROTEIN P73;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DEOXYCYTIDINE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TIME FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 59449096031     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-0220-8     Document Type: Article

References (44)

1. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics, 2007 CA Cancer J Clin. 57 43 66
2. N Bardeesy RA DePinho 2002 Pancreatic cancer biology and genetics Nat Rev Cancer. 2 897 909
3. CM Galmarini JR Mackey C Dumontet 2001 Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia. 15 875 90
4. H Ueno K Kiyosawa N Kaniwa 2007 Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer. 97 145 51
5. D Li Y Li L Jiao 2007 Effects of base excision repair gene polymorphisms on pancreatic cancer survival Int J Cancer. 120 1748 54
6. D Li H Liu L Jiao 2006 Significant effect of homologous recombination DNA repair gene polymorphisms on pancreatic cancer survival Cancer Res. 66 3323 30
7. D Li M Frazier DB Evans KR Hess CH Crane L Jiao 2006 Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer J Clin Oncol. 24 1720 8
8. R de las Penas M Sanchez-Ronco V Alberola 2006 Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients Ann Oncol. 17 668 75
9. CH Bosken Q Wei CI Amos MR Spitz 2002 An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer J Natl Cancer Inst. 94 1091 9
10. SJ Elledge 1996 Cell cycle checkpoints: preventing an identity crisis Science. 274 1664 72
11. J Momand HH Wu G Dasgupta 2000 MDM2-master regulator of the p53 tumor suppressor protein Gene. 242 15 29
12. J Chen X Wu J Lin AJ Levine 1996 MDM-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein Mol Cell Biol. 16 2445 52
13. Y Haupt Y Barak M Oren 1996 Cell type-specific inhibition of p53-mediated apoptosis by mdm2 EMBO J. 15 1596 606
14. M Dong G Ma W Tu KJ Guo YL Tian YT Dong 2005 Clinicopathological significance of p53 and mdm2 protein expression in human pancreatic cancer World J Gastroenterol. 11 2162 5
15. GL Bond W Hu EE Bond 2004 A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell. 119 591 602
16. M Li Z Zhang DL Hill H Wang R Zhang 2007 Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3 K/mTOR/ETS2 pathway Cancer Res. 67 1988 96
17. M Macaluso M Montanari C Cinti A Giordano 2005 Modulation of cell cycle components by epigenetic and genetic events Semin Oncol. 32 452 7
18. HS Zhang AA Postigo DC Dean 1999 Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition Cell. 97 53 61
19. AJ Whelan D Bartsch PJ Goodfellow 1995 Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene N Engl J Med. 333 975 7
20. I Sauroja J Smeds T Vlaykova 2000 Analysis of G(1)/S checkpoint regulators in metastatic melanoma Genes Chromosomes Cancer. 28 404 14
21. LJ Ostruszka DS Shewach 2000 The role of cell cycle progression in radiosensitization by 2 2-difluoro-2-deoxycytidine Cancer Res. 60 6080 8
22. D Kranz M Dobbelstein 2006 Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy Cancer Res. 66 10274 80
23. M Kaghad H Bonnet A Yang 1997 Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell. 90 809 19
24. T Stiewe BM Putzer 2002 Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 9 237 45
25. CA Jost MC Marin WG Kaelin Jr 1997 p73 is a simian [correction of human] p53-related protein that can induce apoptosis Nature. 389 191 4
26. XQ Wang WM Ongkeko AW Lau KM Leung RY Poon 2001 A possible role of p73 on the modulation of p53 level through MDM2 Cancer Res. 61 1598 603
27. D Pfeifer G Arbman XF Sun 2005 Polymorphism of the p73 gene in relation to colorectal cancer risk and survival Carcinogenesis. 26 103 7
28. Y Niwa K Hirose K Matsuo 2005 Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects Cancer Lett. 219 183 90
29. Z Hu X Miao H Ma 2005 Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population Int J Cancer. 114 455 60
30. G Li EM Sturgis LE Wang 2004 Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell carcinoma of the head and neck Carcinogenesis. 25 1911 6
31. G Li LE Wang RM Chamberlain CI Amos MR Spitz Q Wei 2004 p73 G4C14-to-A4T14 polymorphism and risk of lung cancer Cancer Res. 64 6863 6
32. Y Niwa N Hamajima Y Atsuta 2004 Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese Cancer Lett. 205 55 60
33. A Hishida K Matsuo K Tajima 2004 Polymorphisms of p53 Arg72Pro, p73 G4C14-to-A4T14 at exon 2 and p21 Ser31Arg and the risk of non-Hodgkin's lymphoma in Japanese Leuk Lymphoma. 45 957 64
34. BM Ryan R McManus JS Daly E Carton PW Keeling JV Reynolds 2001 A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma Br J Cancer. 85 1499 503
35. H Li L Yao T Ouyang 2007 Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival Carcinogenesis. 28 372 7
36. ML Fero E Randel KE Gurley JM Roberts CJ Kemp 1998 The murine gene p27Kip1 is haplo-insufficient for tumour suppression Nature. 396 177 80
37. O Coqueret 2003 New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 13 65 70
38. J Tsihlias L Kapusta J Slingerland 1999 The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med. 50 401 23
39. CJ Sherr JM Roberts 1999 CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev. 13 1501 12
40. G Li EM Sturgis LE Wang 2004 Association between the V109G polymorphism of the p27 gene and the risk and progression of oral squamous cell carcinoma Clin Cancer Res. 10 3996 4002
41. AS Kibel BK Suarez J Belani 2003 CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma Cancer Res. 63 2033 6
42. BL Chang SL Zheng SD Isaacs 2004 A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer Cancer Res. 64 1997 9
43. Figueiredo JC, Knight JA, Cho S, et al. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer. 2007;7:99.
44. H Ma G Jin Z Hu 2006 Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women Int J Cancer. 119 2173 8